



## Strategies for Combatting Multidrug-Resistant and Extensively Drug-Resistant Bacteria: Current Challenges and Future Prospects

Guest Editors:

**Prof. Dr. Adriána Liptáková**

Comenius University Medical  
School, Bratislava, Slovakia

**Dr. Bożena Futoma-Kołoch**

Department of Microbiology,  
University of Wrocław, Wrocław,  
Poland

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editors

Dear Colleagues,

Antimicrobial resistance is currently considered one of the most important threats to global public health by the World Health Organization. Globally, multidrug-resistant (MDR) and extensively drug-resistant (EDR) bacterial pathogens are spreading. Although the acquisition of resistance is a natural process, the misuse of antibiotics, inadequate surveillance, and the poorly controlled regulation of antibiotics in clinical medicine and in the livestock industry potentiate the uprise and worldwide spread of MDR bacteria.

We should focus on new strategies, including those that are not only related novel antimicrobial drugs but as well as those related to uncommon drug strategies such as use of bacteriophages, autovaccines, or personalized microbiota and antimicrobial stewardship with updated guidelines.

We hope you find this topic exciting and will join our journey to find new and innovative strategies to decrease the mortality and morbidity of patients suffering from MDR and EDR pathogens.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)